Quest PharmaTech (TSXV:QPT) EBIT : C$-22.24 Mil (TTM As of Oct. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Quest PharmaTech EBIT?

Quest PharmaTech's earnings before interest and taxes (EBIT) for the three months ended in Oct. 2023 was C$-2.51 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Oct. 2023 was C$-22.24 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Quest PharmaTech's annualized ROC % for the quarter that ended in Oct. 2023 was -0.91%. Quest PharmaTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Quest PharmaTech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Oct. 2023 was -518.49%.

Quest PharmaTech EBIT Historical Data

The historical data trend for Quest PharmaTech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest PharmaTech EBIT Chart

Quest PharmaTech Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

EBIT

Get a 7-Day Free Trial

-8.64

-13.24

190.07

-85.03

-7.31

Quest PharmaTech Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
EBIT	Get a 7-Day Free Trial															-0.91	-4.75	-5.17	-9.81	-2.51

Competitive Comparison of Quest PharmaTech's EBIT

For the Biotechnology subindustry, Quest PharmaTech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quest PharmaTech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quest PharmaTech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Quest PharmaTech's EV-to-EBIT falls into.

Quest PharmaTech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-22.24 Mil.

Quest PharmaTech (TSXV:QPT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Quest PharmaTech's annualized ROC % for the quarter that ended in Oct. 2023 is calculated as:

	ROC % (Q: Oct. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jul. 2023 )	+	Invested Capital (Q: Oct. 2023 ))	/ count )
=	-0.628 * ( 1 - 0% )	/	( (70.392	+	68.033)	/ 2 )
=	-0.628	/	69.2125
=	-0.91 %

where

	Invested Capital		(Q: Jul. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	69.718	-	0.034	-	( 0.101	-	max(0, 1.034	-	0.326	+	0.101	))
=	70.392

	Invested Capital		(Q: Oct. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	67.337	-	0.165	-	( 0.094	-	max(0, 1.165	-	0.304	+	0.094	))
=	68.033

Note: The Operating Income data used here is four times the quarterly (Oct. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Quest PharmaTech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Oct. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Oct. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jul. 2023		Q: Oct. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-10.024	/	( ( (0 + max(-0.028, 0))	+	(0 + max(-0.165, 0)) )	/	2 )
=	-10.024	/	( ( 0	+	0 )	/	2 )
=	-10.024	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jul. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.006)	-	(0.034	+	0	+	0)
=	-0.028

	Working Capital		(Q: Oct. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0.165	+	0	+	0)
=	-0.165

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Oct. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Quest PharmaTech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Oct. 2023 )
	=	-22.238	/	4.289
	=	-518.49 %

Quest PharmaTech EBIT Related Terms

Thank you for viewing the detailed overview of Quest PharmaTech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Quest PharmaTech (TSXV:QPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quest PharmaTech Inc (TSXV:QPT) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

8123 Roper Road NW, Edmonton, AB, CAN, T6E 6S4

Website

http://www.questpharmatech.com

Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.

Executives

Ragupathy Madiyalakan

Director

Quest PharmaTech (TSXV:QPT) Headlines

No Headlines